The application relates to processes for preparing valganciclovir and pharmaceutically acceptable salts thereof, as well as intermediates for the processes. valganciclovir hydrochloride is represented by Formula II.
该申请涉及制备瓦尔甘西韦及其药用可接受盐的工艺,以及工艺中的中间体。瓦尔甘西韦盐酸盐由二式所代表。
APTAMER FOR NGF AND USE THEREOF
申请人:Ribomic Inc
公开号:EP2551346A1
公开(公告)日:2013-01-30
Provided is a higher quality aptamer having a binding activity to NGF.
An aptamer binding to NGF, which satisfies the following (1) and (2):
(1) containing the sequence represented by UGAAARAAACC (SEQ ID NO: 64) or CGAAMRAAACU (SEQ ID NO: 65), and
(2) having a base length of not more than 73.
本研究提供了一种具有与 NGF 结合活性的高质量适配体。
一种与 NGF 结合的适配体,它满足以下(1)和(2):
(1) 含有由 UGAAARAAACC(SEQ ID NO:64)或 CGAAMRAAACU(SEQ ID NO:65)代表的序列,以及
(2) 碱基长度不超过 73。
Synthesis of Valganciclovir Hydrochloride Congeners
Abstract Valganciclovirhydrochloride (1) is used for the treatment of cytomegalovirus (CMV) retinitis in patients with weakened immune systems. Valganciclovirhydrochloride is a hydrochloride salt of L-valyl ester of ganciclovir (2) that exists as a mixture of two diastereomers. According to the U.S. Food and Drug Administration specifications, the diastereomeric ratio of valganciclovir hydrochloride